Connect your AI

Ardelyx ARDX Change in Deferred Revenue

Change in Deferred Revenue at other companies

Aurinia PharmaceuticalsAUPH

$1.08M-75.1%

Other financials

Income statement

Revenue$94.5M+27.5%

Gross profit$89.7M+45.1%

Operating income-$32.8M+9.8%

Net income-$37.6M+8.6%

EPS (diluted)-$0.15+11.8%

Balance sheet

Cash & equivalents$31.2M+1.3%

Total debt$208.3M+34.3%

Total equity$148.6M+2.0%

Total assets$504.5M+23.0%

Cash flow

Operating cash flow-$32.2M+16.2%

CapEx$69.0K-78.8%

Free cash flow-$32.3M+16.7%

Valuation

Market cap$1.53B+79.5%

Enterprise value$1.71B+74.8%

P/S3.6×+1.2×

Profitability

Gross margin92.5%+7.9pp

Operating margin-25.4%—

Net margin-13.6%—

FCF margin-40.9%—

Returns & leverage

Return on equity-39.5%—

Debt / equity1.4×+0.3×

Current ratio3.5×-0.6×

Where this comes from

Reported directly by Ardelyx in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInDeferredRevenue.

The official record: Ardelyx’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ardelyx's change in deferred revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Ardelyx's change in deferred revenue?: Ardelyx (ARDX) reported change in deferred revenue of $2.04M in Q1 2026.
How has Ardelyx's change in deferred revenue changed year-over-year?: Ardelyx's change in deferred revenue increased by 51.8% year-over-year, from $1.35M to $2.04M.
What is the long-term trend for Ardelyx's change in deferred revenue?: Over 2 years (2021 to 2025), Ardelyx's change in deferred revenue has grown at a 134.1% compound annual growth rate (CAGR), from $550K to -$3.01M.
What does change in deferred revenue mean?: Change in payments received from customers for goods/services not yet delivered — a key SaaS and subscription metric.